[e-farmacos] WHO Pharmaceuticals Newsletter No. 5, 2006

["Madurga, Mariano" <mmadurga@agemed.es>]

Estimadas y estimados,

Acaba de publicarse el WHO Pharmaceuticals Newsletter numero 5, 2006 con el siguiente indice:

Regulatory Matters 
Bevacizumab -- Reports of reversible posterior leukoencephalopathy syndrome (RPLS)..1 

Dexamfetamine sulfate -- Label to warn of sudden death from misuse..1 

Dietary supplement -- Adulterated with estazolam..1 

Diethylene glycol -- Detected in cough syrup; fatalities reported..2 

Hydrogen peroxide -- High strength peroxide not a medical product..2 

Neophase Formula -- Presence of undeclared active ingredient..2 

Safety of Medicines 
Antidepressants -- Update on adverse reaction reports..3 

Bismacine -- Warning against use..3 

Bisphosphonates -- Additional cases of osteonecrosis of the jaw..3 

CFC-free beclometasone inhalers -- Dose adjustments needed with different brands...3 

Enoxaparin -- To decrease dose in renal disease..3 

Ibuprofen -- Interaction with low-dose, non-coated aspirin..4 

Infliximab -- Reports of hepatosplenic non-hodgkin's lymphoma..4 

Jambrulin -- High lead content..5 

Lamotrigine -- In utero exposure and risk of cleft lip and/or palate..5 

Norelgestromin/ethinyl estradiol contraceptive patch -- New study shows increased risk of VTE5 

Sirolimus -- High rate of renal transplant rejection..6 

Feature 
Counterfeit medicines: an intent to deceive..7

Proximamente en:
http://www.who.int/medicines 

Un abrazo,

Mariano Madurga Sanz
Jefe de Servicio de Coordinacion del SEFV
Division de Farmacoepidemiologia y Farmacovigilancia
Agencia Espanhola de Medicamentos y Productos Sanitarios
E-28022-Madrid
(Espanha)
Correo-e: mmadurga@agemed.es